Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

These results were recently published in Nature Medicine in the study titled "Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial." Subscribe to ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...